Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Omar Kayaleh"'
Autor:
Sherise Rogers, Ryan Thomas, Brain Ramnaraign, Ilyas Sahin, Jesus Fabregas, Karen Russell, Steven Hughes, Ibrahim Nassour, Kathyrn Hitchcock, Omar Kayaleh, Anita Turk, Ji-Hyun Lee, David DeRemer, Carmen Allegra, Thomas George
Publikováno v:
Cancer Research. 83:2186-2186
Background: Pancreatic cancer portends a very poor prognosis. It is the third leading cause of cancer deaths in the United States. African Americans have a 50- 90% increased incidence of pancreatic cancer in comparison to other racial groups. 20% of
Autor:
Sherise Rogers, Ryan Thomas, Brian Ramnaraign, Ilyas Sahin, Jesus Fabregas, Karen Russell, Steven Hughes, Ibrahim Nassour, Kathryn Hitchcock, Omar Kayaleh, Anita Turk, Ji-Hyun Lee, David DeRemer, Carmen Allegra, Thomas George
Publikováno v:
Cancer Research. 82:B037-B037
Background: Pancreatic cancer portends a very poor prognosis. It is the third leading cause of cancer deaths in the United States. African Americans have a 50- 90% increased incidence of pancreatic cancer in comparison to other racial groups. 20% of
Autor:
E. Claire Dees, Jaafar Bennouna, A. Craig Lockhart, Bin Zhang, Radka Obermannova, Petr Zatloukal, Omar Kayaleh, Antoine Adenis, Angela DeMichele, Bohuslav Melichar, Claudio Dansky Ullmann, Claudia Schusterbauer
Publikováno v:
The Lancet Oncology. 16:395-405
Summary Background Alisertib is an investigational, oral, selective inhibitor of aurora kinase A. We aimed to investigate the safety and activity of single-agent alisertib in patients with predefined types of advanced solid tumours. Methods We did a
Autor:
Jayne Gurtler, Andrew H. Ko, Terry Katz, Mark Keaton, Eric K. Rowinsky, Hagop Youssoufian, Omar Kayaleh, Heinz-Josef Lenz, Shaila Ballal, Karel Dicke
Publikováno v:
Investigational New Drugs. 30:1597-1606
The purpose of this study was to assess the efficacy and safety of bevacizumab plus cetuximab with or without gemcitabine in patients with advanced pancreatic adenocarcinoma. Patients with locally advanced or metastatic pancreatic adenocarcinoma, pre
Autor:
Gregory K. Pennock, Nikita Shah, Julio Hajdenberg, Jennifer E. Tseng, Clarence H. Brown, Omar Kayaleh, Said Baidas
Publikováno v:
American Journal of Lifestyle Medicine. 3:337-348
Despite evidence that cancer death rates in the United States are declining, the absolute number of new cancers and cancer deaths continues to increase, and there is clear evidence that certain human behaviors are influencing these increases. The 4 m
Publikováno v:
Clinical Cancer Research. 21:A03-A03
Cancer treatment is complicated when patients develop resistance to standard therapies. Hence, developing strategies to address resistance to chemo therapy and improving therapeutic efficiency is of great importance in treating cancer successfully. R
Autor:
Omar Kayaleh, Heinz-Josef Lenz, I. Y. Gong, Cathryn Rankin, Charles D. Blanke, Syma Iqbal, Abby B. Siegel, Kenneth C. Micetich, Anthony B. El-Khoueiry
Publikováno v:
British Journal of Cancer
Background: Gallbladder cancers and cholangiocarcinomas make up a heterogenous group of tumours with a poor prognosis in advanced stages. On the basis of evidence of dysregulation of the epidermal growth factor receptor, vascular endothelial growth f
Autor:
Omar Kayaleh, Mamoru Shoji, Riyaz Basha, Bassel F. El-Rayes, Ganji Purnachandra Nagaraju, Sarah F. Connelly, Umesh T. Sankpal
Publikováno v:
Cancer Research. 74:4216-4216
Tolfenamic acid (TA), a non-steroidal anti-inflammatory drug is known to inhibit human cancer cells and mouse tumor growth in some cancer models. TA is known to target the transcription factor, specificity protein1 (Sp1) that mediates the expression
Publikováno v:
Current medicinal chemistry. 19(22)
Pancreatic cancer is an aggressive malignancy with poor prognosis. Pancreatic adenocarcinoma is one of the leading causes of cancer-related deaths in the United States. Due to the aggressive nature of this malignancy, there is a serious concern for i